Cargando…
DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway
Doxorubicin (Dox) has limited efficiency in breast cancer (BC) due to drug-acquired resistance. The epithelial–mesenchymal transition (EMT) plays a major role in the survival and drug resistance of cancer cells. It was suggested that the JNK pathway was implicated in the response to Dox by regulatin...
Autores principales: | Al-Mutairi, Mashael S., Habashy, Hany O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572343/ https://www.ncbi.nlm.nih.gov/pubmed/36234680 http://dx.doi.org/10.3390/molecules27196146 |
Ejemplares similares
-
Nuclear Factor-κB Clinical Significance in Breast Cancer: An Immunohistochemical Study
por: Al-Mutairi, Mashael Saqer, et al.
Publicado: (2022) -
Camel Urine Promotes Sensitization to Doxorubicin by Inhibiting Epithelial-Mesenchymal Transition and Modulating NF-κB-Snail Signaling Pathway in Breast Cancer Cells
por: Al-Mutairi, Mashael Saqer, et al.
Publicado: (2021) -
Phosphorylation Dynamics of JNK Signaling: Effects of Dual-Specificity Phosphatases (DUSPs) on the JNK Pathway
por: Ha, Jain, et al.
Publicado: (2019) -
Scaffold Role of DUSP22 in ASK1-MKK7-JNK Signaling Pathway
por: Ju, Anna, et al.
Publicado: (2016) -
Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)